Edition:
United Kingdom

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

3,897JPY
24 May 2019
Change (% chg)

¥27 (+0.70%)
Prev Close
¥3,870
Open
¥3,875
Day's High
¥3,898
Day's Low
¥3,822
Volume
1,171,700
Avg. Vol
1,181,913
52-wk High
¥5,829
52-wk Low
¥3,780

Latest Key Developments (Source: Significant Developments)

FDA Approves Taiho Oncology's Lonsurf For Adult Patients With Previously Treated Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::FDA APPROVES TAIHO ONCOLOGY'S LONSURF® (TRIFLURIDINE/TIPIRACIL) FOR ADULT PATIENTS WITH PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA.TAIHO ONCOLOGY INC SAYS FDA APPROVAL OF CO'S LONSURF EXPANDS CURRENT INDICATION FOR LONSURF IN U.S..  Full Article

Health Canada Approves Otsuka & Lundbeck's REXULTI As Adjunctive Treatment Of Major Depressive Disorder
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Otsuka::HEALTH CANADA APPROVES OTSUKA AND LUNDBECK'S REXULTI (BREXPIPRAZOLE) AS ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.  Full Article

Otsuka Holdings Co, Proteus Digital Health Report Expanded Collaboration Agreement
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::OTSUKA AND PROTEUS DIGITAL HEALTH ANNOUNCE EXPANDED COLLABORATION AGREEMENT TO ADVANCE DIGITAL MEDICINES FOR MENTAL HEALTH.OTSUKA PHARMACEUTICAL SAYS AS PART OF EXPANDED COLLABORATION, CO MADE $88 MILLION IN RELATED EQUITY AND OTHER PAYMENTS TO PROTEUS.OTSUKA PHARMACEUTICAL - EXPANDED AGREEMENT COVERS DEVELOPMENT & COMMERCIALIZATION OF DIGITAL MEDICINES OVER NEXT 5 YEARS.  Full Article

Otsuka Holdings to transfer stake management business to unit Otsuka Medical Devices
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says it will transfer ReCor Medical, Inc related stake management business to unit Otsuka Medical Devices Co Ltd, effective Nov. 1 .  Full Article

DKSH: Otsuka Extends Partnership With DKSH In Hong Kong
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - DKSH Holding AG ::OTSUKA EXTENDS PARTNERSHIP WITH DKSH IN HONG KONG.  Full Article

Otsuka Holdings unit completes acquisition of U.S.-based firm Visterra
Monday, 3 Sep 2018 

Sept 3 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says its unit Otsuka Pharmaceutical Co., Ltd completed acquisition of U.S.-based firm Visterra Inc on Aug. 31 .  Full Article

Astex Pharmaceuticals And Otsuka Announce Results Of The Phase 3 Astral-1 Study Of Guadecitabine In Treatment-Naïve AML Patients Ineligible To Receive Intense Induction Chemotherapy
Monday, 30 Jul 2018 

July 30 (Reuters) - ASTEX PHARMACEUTICALS ::ASTEX PHARMACEUTICALS AND OTSUKA ANNOUNCE RESULTS OF THE PHASE 3 ASTRAL-1 STUDY OF GUADECITABINE (SGI-110) IN TREATMENT-NAÏVE AML PATIENTS INELIGIBLE TO RECEIVE INTENSE INDUCTION CHEMOTHERAPY.ASTEX PHARMACEUTICALS - STUDY DID NOT MEET ITS CO-PRIMARY ENDPOINTS.ASTEX PHARMACEUTICALS SAYS CONTINUES TO FOCUS ON COMPLETING PHASE 3 ASTRAL-2 AND ASTRAL-3 STUDIES.  Full Article

Otsuka Holdings unit to fully acquire U.S.-based firm Visterra via unit for $430 mln
Thursday, 12 Jul 2018 

July 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says wholly owned unit Otsuka Pharmaceutical Co., Ltd plans to fully acquire U.S.-based firm Visterra Inc via unit Otsuka America, Inc. in the third quarter for fiscal year 2018.Acquisition price is $430 million.  Full Article

Otsuka Medical Devices, Otsuka Holdings And Recor Medical Announce Signing Of Merger Agreement
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::OTSUKA MEDICAL DEVICES, OTSUKA HOLDINGS AND RECOR MEDICAL ANNOUNCE SIGNING OF MERGER AGREEMENT.MERGER AGREEMENT PURSUANT TO WHICH OTSUKA HOLDINGS WILL ACQUIRE REMAINING SHARES IN RECOR FROM ITS CURRENT HOLDERS.  Full Article

Otsuka Holdings unit and Lundbeck to start third phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with Alzheimer's disease
Thursday, 24 May 2018 

May 24 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co Ltd and Lundbeck announce that the two companies' third clinical phase 3 study ofbrexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.  Full Article